Literature DB >> 7716163

Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs B1 and B5 as single-chain immunotoxins.

I Benhar1, I Pastan.   

Abstract

The mAbs B1 (IgG1 kappa) and B5 (IgM kappa) recognize carbohydrate epitopes on human carcinoma cells. The Fv regions of these antibodies were separately cloned from hybridoma RNA using reverse transcription and PCR with oligonucleotide primers designed according to the amino acid sequences of the N-termini. The Fv regions also provide sequences for translation initiation in Escherichia coli (Fr1 oligos) and sequences of the constant region of the heavy and light domains (CH1 or C-kappa oligos). Following the determination of the DNA sequence of the Fvs, primers were designed according to the 3' ends of the VH and VL domains. These also provided for a peptide linker at the C-terminus of the VH and a short connector at the C-terminus of the VL (Fr4 oligos). The VH and VL were then each PCR-amplified using their corresponding Fr1 and phosphorylated Fr4 oligos. The resulting PCR products were annealed as 'mutagenic primers' to a uracil-containing single-stranded template obtained from an expression plasmid encoding a single-chain immunotoxin in which the B3 single-chain Fv is fused to a truncated form of Pseudomonas exotoxin (PE). Thus, the B1 and B5 variable domains replaced their corresponding B3 domains in the expression plasmid by 'variable domain shuffling' without subcloning. The resulting B1(Fv)-PE38 and B5(Fv)-PE38 were expressed in E. coli and purified to near homogeneity. Both show specific cytotoxicities to human carcinoma cell lines, but B1(Fv)-PE38 is much more active, reflecting its higher affinity to the target cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7716163     DOI: 10.1093/protein/7.12.1509

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  5 in total

1.  Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions.

Authors:  S Barth; M Huhn; B Matthey; A Klimka; E A Galinski; A Engert
Journal:  Appl Environ Microbiol       Date:  2000-04       Impact factor: 4.792

2.  Random recombination of antibody single chain Fv sequences after fragmentation with DNaseI in the presence of Mn2+.

Authors:  I A Lorimer; I Pastan
Journal:  Nucleic Acids Res       Date:  1995-08-11       Impact factor: 16.971

3.  Antibody-Mediated Inhibition of Insulin-Degrading Enzyme Improves Insulin Activity in a Diabetic Mouse Model.

Authors:  Ofir Fursht; Mirit Liran; Yuval Nash; Vijay Krishna Medala; Dor Ini; Tabitha Grace Royal; Guy Goldsmith; Limor Nahary; Itai Benhar; Dan Frenkel
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

4.  Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.

Authors:  Malka Epel; Irit Carmi; Sharon Soueid-Baumgarten; SangKon Oh; Tapan Bera; Ira Pastan; Jay Berzofsky; Yoram Reiter
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 6.688

5.  Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.

Authors:  C T Kuan; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 12.779

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.